The method of improving the treatment of steroid ointments


(57) Abstract:

The invention relates to medicine, in particular for Allergology and dermatology, and for the treatment of atopic dermatitis. The method is topically applied on the lesions steroid ointment, optionally containing heparin, the dose steroids reduce the 13 - 40 times. The method increases the effect of treatment and reduce complications of steroid therapy. 3 table.

The technical field. The invention is related to medicine, can be used in Allergy, Pediatrics and dermatology, is a method of treatment of allergic skin diseases in both adults and children.

The prior art. There is a method of treatment of allergic diseases of the skin through the use of ointments containing corticosteroids. However, use of these ointments is accompanied by serious complications, such as decreased immunity, secondary infection, the development of dystrophic skin changes and fibrosis, changes such as ichthyosis, skin discoloration, acne, dermatitis, like rosacea, perioral dermatitis, purpura, photosensitive dermatitis, telangiectasia, girs is but the use of heparin in the treatment of allergic reactions of the delayed type, for example, glomerulonephritis, to increase the efficiency of action of glucocorticosteroids. In addition, when using heparin not only improves local microcirculation, but it is known that heparin is an antagonist of histamine, which is the main cause of allergic inflammation (2).

The disadvantage of this method is that in the treatment of glomerulonephritis is used parenteral route of administration of heparin, which requires constant monitoring of the blood coagulation system. Allergic diseases of the skin is topically applied heparin that will save patients from more invasive methods of monitoring the status of the blood coagulation system because topical application of heparin does not cause changes in the coagulation system.

The essence of the claimed method is that in contrast to the known method of application of heparin in combination with corticosteroids, parenteral and enteral encouraged to apply by heparin and corticosteroids topically in the form of ointments, with the reduction of glucocorticosteroids in 13-40 times reduces the risk of complications caused by the use of hormonal ointments (1).

The invention jaw complications associated with their use.

List of tables:

Table 1.

The dose of the active substance in terms of prednisolone in the ointment.

1 - 1% hydrocortisone ointment (in terms of prednisolone 1 g - 0,25 active substances);

2 - 0.5% prednizolonovuyu ointment, (1 g - 0,5);

3 - 0.1% ointment "tselestoderm", (1 g - 0,75);

4 - 0,0025 % ointment with the addition of heparin (1 g - 0,01875)

Table 2.

The ratio of active ingredient content in terms of prednisolone in the ointment.

5 - 1% hydrocortisone ointment - 13,3;

6 - 0.5% prednizolonovuyu ointment - 26,6;

7 - 0.1% ointment "tselestoderm" - 40;

8 - 0,0025% ointment with added heparin - 1

Table 3.

The efficacy of the ointment in children with atopic dermatitis.

1 - application of ointments containing hydrocortisone;

2 - application of ointments containing prednisolone;

3 - apply the ointment "tselestoderm";

4 - application of ointments containing heparin;

the average duration of treatment of patients with severe atopic dermatitis;

the average duration of treatment of patients with moderate atopic dermatitis;

the concentration of corticosteroids Easie glucocorticosteroids, used 20 children with severe and 20 children with moderate current atopic dermatitis. In each group of 5 children applied the ointment containing hydrocortisone, prednisolone 5, 5 "celestoderm" and 5 ointment with reduced content of corticosteroids compared with the above ointments 13.3-40 times and heparin (table 1, 2).

Studies have shown that the average duration of treatment with an ointment containing hydrocortisone, averaged in severe disease 35, and at moderate 17 days. Children using for the treatment of ointment containing prednisolone, when severe disease noted the average efficiency of 27, while moderate on day 15. "Tselestoderm" proved to be effective in children with severe disease on 14 and with moderate on the 7th day. Ointment containing heparin, has effect in severe atopic dermatitis on the 7th day, while moderate on day 3 of the disease (table 3).

An example of a specific application of ointments containing heparin:

Baby K. 8 months with a diagnosis of atopic dermatitis, a common form of severe, acute dermatitis was received as a healing various ointments containing corticosteroids in the to notice a decrease in the efficacy of the drug, therefore I went to the doctor. The purpose of ointments containing heparin, had a significant effect on the 3rd day of use and after 7 days of symptoms of dermatitis is almost completely absent.

Child A. 5 years with a diagnosis of atopic dermatitis, localized form, moderate flow, used various ointments containing corticosteroids. The effect of applying in a few months was incomplete, because it remained manifestations of lichenification in typical dermatitis. After using the ointment with heparin manifestations of dermatitis, including lichenification, disappeared on the 5th day from the start of treatment.


1. On The Main Page. Drugs in Russia: a Handbook. M: Attraversare, 1991

2. Vinogradov Centuries, N. Vorobyov.F. Fat cells. Novosibirsk., - 1973.

3. Clinical Pharmacy and Therapeutics/ editors, E. T. Herfindal, D. R. Gourley, L. L. Hart. - 5ch ed. 1998.

A method of treating atopic dermatitis by topical use of steroid ointments, characterized in that the ointment further comprises heparin, the dose of corticosteroids decrease in the 13 - 40 times.


Same patents:

-adrenergic agonist as an antagonist of substance p" target="_blank">

The invention relates to medicine, namely to dermatology, and concerns the use of at least one-adrenergic agonist in cosmetic compositions as an antagonist of substance P for the treatment of diseases associated with excessive synthesis and/or release of substance P

The invention relates to medicine, namely to dermatology
The invention relates to medicine applies balm-ointment for the treatment of deep and extensive burns and infected wounds and ulcers

The invention relates to chemical-pharmaceutical industry, refers to a stable solution palmitate, treatment of skin diseases and reducing the side effects of chemotherapy for cancer patients

- cyano)-,-diphenylethylamine, use,- diphenylacetamide or (-cyano)-,- diphenylacetate, the method of stabilization of the composition and method of cosmetic treatment of the skin and/or hair" target="_blank">

The invention relates to novel cosmetic and/or dermatological compositions comprising cosmetically and/or dermatologically acceptable medium, 4-tert.-butyl-4'-methoxybenzanilide at least one derivative of 1,3,5-triazine, at least,-diphenylacetamide or (-cyano)-,-diphenylethylamine, as well as to a method of stabilization and to a method of cosmetic treatment of the skin and/or hair

The invention relates to the development of safe and effective tools that increase the speed of delivery of physiologically active agents through the skin or mucous membrane of the mouth

The invention relates to medicine and the pharmaceutical industry and relates to a means of stimulating the reparative processes in tissues

The invention relates to medicine, namely to surgery
The invention relates to medicine, more specifically to trauma, and can be used to accelerate the consolidation of diaphyseal fractures of the tibia after a stable immobilization of the fragments

The invention relates to the field of biology, in particular biochemistry

The invention relates to a new anti-adhesion agent
The invention relates to the use of chitosan and fixed it polysaccharide selected from heparin, heparan sulfate, chondroitin sulfates and dextransucrase, as agent, capable of providing stimulated the regeneration of hard tissues

The invention relates to biology, in particular biochemistry

The invention relates to medicine, specifically to Hematology, and can be used for pharmacological correction of disorders in the blood system under cytostatic mielodepressii